Study of AT-527 in Healthy and HCV-Infected Subjects
Completed
Atea Pharmaceuticals, Inc.
Phase 1
This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics
(PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV). In
addition, the study will assess the antiviral activity of AT-527 in subjects infected with
HCV.
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
Suspended
Atea Pharmaceuticals, Inc.
Phase 1/Phase 2
This study has two parts. Part A will assess the safety, tolerability and pharmacokinetics
(PK) of AT-777 in healthy subjects. Part B will assess the safety, antiviral
activity/efficacy and PK of AT-777 in combination with AT-527 after 8 weeks of treatment in
HCV-infected subjects.
Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting
Recruiting
Atea Pharmaceuticals, Inc.
Phase 2
The objectives of this study are to evaluate the safety, tolerability, antiviral activity and
efficacy of AT-527 in adult subjects ≥18 years of age with moderate COVID-19 and risk factors
for poor outcomes (such as obesity (BMI>30), hypertension, diabetes or asthma). Eligible
subjects will be randomized to blinded AT-527 (nucleotide analog) tablets or matching placebo
tablets to be administered orally for 5 days. Part A will evaluate an AT-527 dose of 550 mg
BID and Part B will evaluate a second dose of AT-527 (Dose B). Local supportive standard of
care (SOC) will be allowed for all subjects. Efficacy, antiviral activity and safety
observations will be compared for treatment with active AT-527 tablets vs. placebo tablets.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
